REDWOOD CITY, Calif. — August 27, 2025 — Leads & Copy — Rezolute, Inc. (Nasdaq: RZLT) will participate in investor conferences in September, including the Cantor Global Healthcare Conference from Sept. 3-5, the H.C. Wainwright 27th Annual Global Investment Conference from Sept. 8-10, and the Morgan Stanley 23rd Annual Global Healthcare Conference from Sept. 8-10.
Management will participate in fireside chats and one-on-one investor meetings. Investors interested in scheduling a meeting should contact their Cantor, H.C. Wainwright, and Morgan Stanley representatives.
Rezolute is focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). The company’s antibody therapy, ersodetug, is designed to treat all forms of HI.
Christen Baglaneas can be reached at cbaglaneas@rezolutebio.com or 508-272-6717.
Source: Rezolute, Inc.
